Quantitative Image Analysis Laboratory



Providing comprehensive imaging biomarker support.

The University of Colorado Quantitative Image Analysis (QIA) Laboratory (formerly called BIRL) is a core lab devoted to the development and analysis of imaging-based biomarkers.  The laboratory provides comprehensive services for pre-clinical and clinical imaging studies, including protocol development, quality control, analysis, visualization, data reporting, and regulatory compliance. Areas of ongoing collaboration span many specialties including oncology, psychiatry, neurology, endocrinology, exercise and aging. Clients range from large pharmaceutical companies engaged in Phase III clinical trials to local researchers doing pilot studies.

QIA has strong historical and practical links to imaging efforts with other academic groups, including the Oregon Brain Imaging Research Laboratory (O BIRL), The Schizophrenia Research Group, The Brain Imaging Center, The Center For Human Simulation (Visible Human Project), and the Small Animal Imaging Lab.

QIA is directed by Dr. Ann Scherzinger.


Address & Phone: 
University of Colorado/QIA
12700 E. 19th Ave., C278
Aurora, CO  80045     

QIA uses state-of-the-art analysis technology to meet the needs of its clients.  Whether it’s characterizing tumor progression, bone regrowth, radiopharmaceutical uptake or fat content, we can assist you in analyzing, visualizing and reporting on your biomarker of interest.

The laboratory employs a variety of commercial, research and validated custom tools to tackle your particular challenge.  If you need something special, it’s not a problem.  Our scientists can work with you on functional requirements, validation and implementation.

QIA also supports visualization and rendering of large datasets.  From 10 micron resolution tissue samples on microCT to donor livers on MRI, QIA is able to generate high-quality 3D renderings and meshes to suit your needs.

QIA offers a comprehensive suite of services to aid pharmaceutical, government and investigator-initiated studies.  Our services meet regulatory requirements for GxPHIPAA and 21 CFR 11. Please review our service center rate sheet for QIA FY17 pricing​​.​


  • Selection of Relevant Imaging Biomarkers
  • Determination of Sample Size
  • Imaging Intervals
  • Image Acquisition Parameters





  • Lesion Tracking
  • Segmentation and Volumetrics
  • Brain Atrophy
  • fMRI
  • Dynamic Imaging
  • CT and MRI Adipose Tissue Quantification
  • Bone densitometry
  • Diffusion Tensor Imaging
  • PET SUV measures (2D or 3D)
  • Magnetic Resonance Spectroscopy


If your core business isn’t the assessment of radiological images or the use of radiation, how do you effectively evaluate a centralized radiology reading center, provide IRBs and regulatory agencies with safety information, or assess novel imaging techniques or analyses? What HIPAA issues and technology hurdles will impact your operations and data submission timelines? QIA can provide valuable insight during the due diligence and startup processes.


If you're awash in a sea of strange acronyms and technology, we can help.  QIA provides quality educational services to transform even the most daunting of technologies into a concise, comprehensible framework.  Whether you need support for your clinical development group, CRAs, medical writers or investigators, QIA keeps you informed and educated in the fast-paced world of medical imaging and radiation technology.


A new imaging technique looks promising for your clinical study. But what are the pitfalls of implementing it in a multi-site environment? What factors may bias the results or drown out that important signal with noise? If you’re going to invest in an imaging biomarker, consult with QIA regarding protocol design, feasibility, optimization and quality control issues and services.


Don’t try looking it up in a book. With the advent of multi-slice CT, dual modality systems and increasingly complicated imaging protocols, estimating patient radiation dose can be a daunting task. QIA provides concise, accurate dose estimates for your imaging studies that can be submitted for IRB and regulatory review.

So you know the radiation dose, but what does that mean? Age, organ type, exposure duration and frequency are just some of the factors that can influence health risks. Know the risks associated with your imaging study so you can better inform your subjects and comply with GCP requirements.

Since the late 1980s QIA (formerly called BIRL) has provided image analysis and radiology review services for translational research and drug development, ranging from pre-clinical studies to large, international drug trials.  Our services have been instrumental in the testing of new compounds, particularly in multiple sclerosis and the FDA approval of Avonex™.

The lab is composed of GCP and HIPAA certified professionals who have extensive training and experience in radiology, medical physics, computer science and clinical trials management.  QIA provides experienced project managers, interfacing with both sponsors and sites to ensure the timely receipt, review and reporting of quality data.

A sampling of past industry clients includes GenentechBristol-Meyers SquibbBiogen Idec, PDL Biopharma and large contract research organizations such as PPD and Covance.  QIA supports local researchers at the University of Colorado, National Jewish Health, The Children’s Hospital, the Veteran’s Affairs Hospital and the CU Cancer Center.